Home › Schizophrenia › NCT07369154
52-week Open Label Safety-Tolerability Study
RecruitingPhase 3
A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
Who can join
Ages 18 to 65 · All sexes
Full eligibility criteria
Inclusion Criteria: * Provide ICF * Patients clinically stable PANSS \</= 80 at screening * CGI-S \</+ 3 at screening * Medically stable * BMI 18 -40 * Taking oral antipsychotic treatment for at least 30 days * Have stable living environment Exclusion Criteria: * Sexually active M/F patients not willing to use highly effective contraception * Breast feeding * History of treatment resistance to schizophrenia medications * DSM-5 current diagnosis other than schizophrenia * Risk of suicidal behavior * History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other
About the study
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
What is being tested
- LB-102 (drug)
Sponsor: LB Pharmaceuticals Inc. · Participants: 900 · Started: Apr 23, 2026
Contact the study team
- Branislav Mancevski, MD · Phone: 212-605-0300
Official record on ClinicalTrials.gov — NCT07369154
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.